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Increasing resistance of pathogens to anti-infective drugs is an urgent public health problem 
that must be addressed through more prudent use of these drugs in human medicine and 
in animal husbandry, agriculture, and aquaculture.Almost all microbes that infect 
humans, and for which there are 
anti-infective drugs, have developed 
some degree of resistance to these 
drugs, and at a pace more rapid than 
anticipated (Table 1). Anti-infective 
drug resistance costs money and 
human lives. Infections caused by 
drug-resistant pathogens are asso-
ciated with increased morbidity and 
mortality, prolonged hospital stays, 
greater direct and indirect costs, 
prolonged periods during which indi-
viduals are infectious, and greater 
opportunities for the spread of infec-
tion to others. Recent estimates of 
the relationship between resistance 
of pathogens to anti-infective drugs 
and health care costs suggest that 
patients in the United States infected 
with drug-resistant organisms incur 
average costs ranging from $6000 to 
$30,000; and that mortality, morbid-
ity, and length of hospitalization all 
increase as anti-infective drug resist-
ance continues to develop in staphy-
lococci, enterococci, and gram-neg-
ative bacilli (Cosgrove, 2006).
Anti-Infective Drugs and the 
Microbes They Treat
The microbes that cause infectious 
diseases are complex, dynamic, 
and constantly evolving. They repro-
duce rapidly, mutate frequently, 
freely exchange genetic material, 
and adapt with relative ease to new 
environments and hosts. Through 
these mechanisms, microbes read-
ily develop resistance to the anti-
infective drugs used to treat them. 
A few years after antimicrobial drugs became widely available post-World 
War II, warning signs of anti-infective 
drug resistance began to appear. 
By the end of the 1940s, for exam-
ple, soon after the introduction and 
widespread use of penicillin, the 
prevalence of penicillin-resistant 
hospital strains of staphylococcus 
in the United Kingdom was 14%. By 
the end of the 1990s, staphylococ-Cell 124, Felarial drugs and intensified control of 
its mosquito vector in the early part 
of the twentieth century, the inci-
dence of malaria rapidly decreased, 
and in the case of the Southern 
United States and Southern Europe 
disappeared. In the 1940s, tubercu-
losis (TB) hospitals in Europe and the 
United States started to empty as liv-
ing conditions improved and effective Table 1. Antimicrobial Resistance Rates (2005)
Malaria 0%–82% chloroquine resistance
Tuberculosis 0%–17% primary multi-drug resistance 
(3% mean worldwide)
HIV 0%–25% primary resistance to at least 
one antiretroviral drug
Gonorrhea 5%–98% penicillin resistance
Pneumonia and bacterial meningitis 0%–70% penicillin resistance
(Streptococcus pneumoniae)
Hospital infections 0%–70% resistance to all penicillins and 
cephalosporins
Source: WHO Policy Perspectives on Medicine, 2005.cal resistance worldwide had risen to 
levels of 95% or greater, and Staphy-
lococcus aureus had accumulated 
resistance genes to virtually all cur-
rently available antimicrobial drugs, 
with methicillin-resistant infections 
disseminated in hospital settings 
and communities (Levy, 1992).
These warning signs were largely 
ignored, however, as new anti-infec-
tive drugs continued to be developed, 
and as the incidence and prevalence 
of infectious diseases in industrial-
ized countries steadily declined. With 
the widespread availability of antima-drugs became available to treat those 
with acute TB, preventing infection of 
patient contacts (also see the Essay 
by D. Young and C. Dye, page 683 of 
this issue). Simultaneously, a host of 
hospital-acquired infections that had 
endangered the lives of hospitalized 
patients and health workers came 
under better control, and sexually 
transmitted infections could easily 
be cured (Armstrong, Conn, Pinner, 
1999).
Despite this progress, more than 14 
million humans continue to die each 
year from infectious diseases, mostly bruary 24, 2006 ©2006 Elsevier Inc. 671
Figure 1. Leading Causes of Mortality in Low-Income Nations (2004)in developing countries where it is 
estimated that infectious diseases 
represent 46% of all deaths (Fig-
ure 1). Approximately 90% of these 
deaths are from six major infections: 
diarrhoeal diseases; acute respira-
tory infections; malaria and measles 
among children less than 5 years 
of age; and AIDS and tuberculosis, 
mainly among adults (WHO, 1999). 
Anti-infective drugs save lives, but 
as resistance to them continues to 
emerge in a host of pathogens their 
effectiveness wanes. Resistance to 
anti-infective drugs has contributed 
to recent increases in infectious dis-
ease mortality worldwide and is an 
urgent public health problem.
Anti-Infective Drugs: Rapid 
Evolution of Resistance
In New York City in the 1990s, multi-
drug-resistant strains of Mycobacte-
rium tuberculosis gained a foothold 
in hospitals and prisons and among 
homeless populations. Simulta-
neously, multidrug-resistant TB 
emerged in the Russian Federation 
and its incidence more than doubled 
in less than seven years, with over 
20% of TB patients in prison set-
tings infected with multidrug-resist-
ant strains. In 2000, it was estimated 
that approximately 3% of all TB 
infections worldwide were multidrug 672 Cell 124, February 24, 2006 ©2006 Eresistant, and that percentage con-
tinues to increase (Dye et al., 2002). 
Whereas a single six-month course 
of drug treatment for nonresistant 
pulmonary TB costs as little as $20, 
treatment for multidrug-resistant TB 
can cost well over $2000 because 
of increased costs for second-line 
drugs, prolonged hospitalization, 
and longer treatment regimens. Such 
high costs put these drugs beyond 
the realm of many developing coun-
tries, and in some TB can no longer 
be effectively managed, resulting in 
increased mortality from this dis-
ease. Finally, treatment failure in TB 
patients with multidrug-resistant 
infections who are then treated with 
second-line drugs range from 20% 
to 40%, necessitating additional 
treatment with even more expensive 
drugs that often have unpleasant 
side effects.
By 1976, resistance of the malaria 
parasite Plasmodium falciparum 
to the cheap and effective frontline 
drug, chloroquine, was widespread in 
southeastern Asia; by the mid-1990s 
resistance to chloroquine was world-
wide. Worse yet, the malaria parasite 
has also developed high-level resist-
ance to two second-level antimalar-
ials, sulfadoxine-pyrimethamine and 
mefloquine. Currently resistance is 
developing to antimalarial drugs with lsevier Inc.increasing rapidity, and it is now rec-
ommended that multidrug combina-
tions be used, each with independent 
modes of action and different bio-
chemical targets, in an effort to slow 
the development of resistance and 
better preserve existing antimalarial 
drugs. This is especially true for the 
newer antimalarial drugs such as the 
artemesinin derivatives (Jung et al., 
2004). Mortality estimates from pub-
lic health records in Africa indicate 
2- to 11-fold increases in malaria-
associated mortality among children 
when drug resistance develops, with 
hospital attendance and admissions 
showing similar increasing trends.
In the 1970s, Neisseria gonor-
rhoeae resistant to the usual doses 
of penicillin was introduced into 
Europe and the United States from 
Southeast Asia, where it is thought 
to have emerged; by the mid-1990s 
resistance of this bacterium to peni-
cillin had spread worldwide. Low-
cost antibiotics such as penicillin 
can no longer be used to treat gonor-
rhea, and gonococcal strains resist-
ant to all major families of antibiotics 
have now been identified wherever 
these antibiotics have been widely 
used. Some countries report that 
more than 70% of gonococcal infec-
tions are caused by bacteria that are 
resistant to the quinolone ring (the 
active moiety of many antibiotics).
Nor have antiviral drugs been 
spared. Resistance to antiretroviral 
drugs among 96 treatment naive 
HIV-infected individuals in Mexico, 
for example, was reported at 6% 
for delaviridine and nevirapine, 4% 
for efavirenz, and 2% for almivudine 
and nelfinavir (Escoto-Delgadillo et 
al., 2005). Similar levels of resist-
ance have been found among HIV 
treatment naive patients in the Horn 
of Africa and elsewhere, necessitat-
ing the use of multidrug combina-
tions in order to slow the evolution 
of HIV strains resistant to current 
antiretrovirals.
Last year, 91% of influenza infec-
tions in the United States—caused 
by influenza virus A strain H3N2—
were found to be resistant to both 
adamantadine and rimantadine, 
two drugs regularly used to treat 
seasonal influenza (CDC, 2005). 
Resistance has not yet developed 
to two other drugs (oseltamivir and 
zenamivir) used to treat this strain of 
influenza, but there is great fear that 
resistance to these two drugs will 
also eventually develop. In Thailand, 
low-level resistance to oseltami-
vir appears to have developed in 
sporadic human infections caused 
by the H5N1 avian influenza virus 
strain (de Jong et al., 2005). This 
has raised serious concerns given 
that the H5N1 strain continues to 
cause sporadic human infections 
and poses a pandemic threat (see 
the Commentary by A. Fauci, page 
665 of this issue).
Anti-Infective Drug Resistance: Its 
Impact and Evolution in Humans
The natural phenomena that cause 
the development of drug resistance—
mutation at anti-infective target sites, 
the acquisition of resistance mecha-
nisms by genetic transfer—are exac-
erbated and amplified by events that 
increase the selective pressure on 
anti-infective drugs. These include 
the misuse of anti-infective drugs in 
the treatment of human and animal 
illnesses and indiscriminate use in 
animal husbandry, aquaculture, and 
agriculture.
It is paradoxical that selective 
pressure due to misuse of anti-infec-
tive drugs can be increased by either 
under use or over use. In developing 
countries, it is inadequate or incon-
sistent access to drugs leading to 
truncated treatment, or a failure to 
take the full course of therapy, that 
increase selective pressure. This is 
compounded by self-prescription 
and purchase of anti-infective drugs 
on the open market due to lack of 
enforcement of legislation or the sale 
of counterfeit drugs with substand-
ard or insufficient active ingredients. 
Between January 1999 and October 
2000 alone, among 46 confidential 
reports of counterfeit drugs from 20 
countries, 32% contained no active 
ingredient, and the rest either had 
incorrect quantities of active ingre-
dients, extraneous ingredients, or 
impurities. In many developing coun-
tries, the higher cost and limited availability of the few remaining sec-
ond-line anti-infective drugs makes 
them an unrealistic choice where 
they are most needed.
In industrialized countries, it is 
often the overprescribing of antibiot-
ics by health workers and excessive 
demand for antibiotics by the general 
population that increase selective 
pressure and amplify the selection 
and survival of resistant microbes. 
Antibiotics are often prescribed 
empirically in the absence of labo-
ratory confirmation of infection. In 
a study on the management of ton-
sillitis in 17 European countries, for 
example, between 68% and 100% of 
patients were prescribed antibiotics, 
and in more than 40% of these cases 
prescription was empirical. In Can-
ada, as many as half of the 26 million 
antibiotic prescriptions dispensed 
annually are estimated to be unnec-
essary (Kondro, 1997), and during a 
recent year in the United States, 12 
million antibiotic prescriptions were 
provided to adults for upper respira-
tory tract infections where they have 
little or no effect.
Over-use and under-use of antibi-
otics occurs simultaneously in most 
countries, however, and is linked 
to economic status and the ability 
to pay for healthcare. In Thailand, 
over the course of a year, 60% of 
viral infections were improperly 
treated with an antibiotic, and 89% 
of bacterial infections were cor-
rectly treated with an antibiotic, 
most often amoxicillin (Suttajit et al., 
2005). Those receiving antibiotics 
were young, male, and could afford 
to pay, whereas significantly fewer 
antibiotics were used to treat non-
paying patients.
Indiscriminate Use in Animal 
Husbandry, Aquaculture, and 
Agriculture
Anti-infective drugs are vital in the 
treatment of infections in animals. 
In many countries, 50% of all anti-
infective drug production each 
year is for animal husbandry. Anti-
biotics are added to animal feed 
(particularly that of pigs and poul-
try) for mass prophylaxis against 
infections or for growth promotion, Cell 124, Feband to water to treat fish diseases. 
Anti-infective drugs are considered 
important for sustainable livestock 
production and for the control of 
animal infections that can be passed 
on to humans as zoonoses.
Certain anti-infective drugs 
administered to animals are also 
used for disease control in humans 
resulting in selection for crossresist-
ance in microbes that are important 
in human medicine or for resistant 
organisms that can be passed from 
animals to humans. The relationship 
between the increase in prevalence 
and distribution of drug-resistant 
infections and the use of antibiotics 
in animals is poorly understood, but 
they are clearly related.
Anti-infective drugs are often used 
as pesticides for treating fruit trees 
and other agricultural products rang-
ing from rice to orchids. In the United 
States, about 300,000 pounds of 
oxytetracycline and streptomycin are 
sprayed on fruit trees each year to 
prevent infection with Erwinia amy-
lovora, the bacterial cause of fire 
blight (NAS, 1998). Development 
and transfer of drug resistance to 
other organisms may be caused by 
such agricultural use. There is, how-
ever, little hard evidence to show the 
importance that anti-infective use in 
agriculture has on the environment 
and on human infections, principally 
because of the difficulty in attributing 
risk to practice.
International Spread of Anti-
Infective Drug Resistance
Drug-resistant organisms are not 
only a problem locally, they can 
also spread rapidly throughout the 
world in humans, animals, vectors, 
or food (WHO, 2001). In 1997, the 
multidrug-resistant serotype 23F of 
Streptococcus pneumoniae, which 
caused an outbreak of infection in a 
daycare center in South Africa, was 
found to be identical to a clone iso-
lated in Spain and also to strains cir-
culating in Korea. Meanwhile, multi-
drug-resistant salmonella isolates 
arrived in Denmark through import-
ing infected boar from Canada; such 
isolates have spread internationally 
via livestock including horses.ruary 24, 2006 ©2006 Elsevier Inc. 673
Improved Use of Anti-Infective 
Drugs
Greater efforts must be made to 
reduce selective pressure on anti-
infective drugs. There is a lack of 
scientific and medical evidence to 
indicate how this can be done, but 
all aspects of anti-infective drug 
use in humans, animals, and agri-
culture must be addressed. It is not 
clear how to prioritize interventions, 
and so a broad strategy is required. 
This strategy necessitates more 
prudent use of antibiotics in human 
medicine, in animal medicine, and 
in animal husbandry/agriculture and 
measures to prevent the spread of 
drug-resistant organisms, including 
better surveillance because border 
controls are difficult to enforce and 
are not effective. Although these 
measures apply to both developed 
and developing countries, the bal-
ance between activities must be tai-
lored to the quantity and patterns of 
anti-infective drug use.
Many infections can be prevented 
and transmission reduced through 
simple, cheap, and effective meas-
ures such as hand washing, the use 
of bed nets, condoms, and vaccina-
tion, and avoidance of unnecessary 
injections, especially where syringes 
and needles are re-used. The gen-
eral population can be educated 
through targeted campaigns with 
a clear message that emphasizes 
when anti-infective drugs should be 
used and when they should not, as 
well as the dangers of their overuse. 
In Singapore, hand washing during 
the 2004 outbreak of severe acute 
respiratory infection (SARS) was 
shown to be protective in preventing 
transmission of SARS within hospi-
tals (Curtis, Cairncross, 2003), and a 
meta-analysis of seven intervention 
studies suggests that hand washing 
in the community can reduce the risk 
of diarrhoeal disease by up to 47%. 
Current television campaigns in 
France emphasize the correct use of 
anti-infective drugs, and similar cam-
paigns in Canada during the 1990s 
were shown to markedly decrease 
requests for antibiotics.
Healthcare providers should be 
taught about the importance of 674 Cell 124, February 24, 2006 ©2006accurate diagnosis and management 
of common infections, infection con-
trol, and disease prevention through-
out their training as well as through 
in-service education. The develop-
ment and use of clinical guidelines 
at each level of care containing cur-
rently recommended doses and 
duration of treatment (as well as the 
maximum use of the recommended 
drug combinations for treating HIV, 
TB, and malaria) are also strongly 
recommended.
Other measures include stronger 
and more rapid diagnosis of infec-
tious diseases and restricting avail-
ability to prescriptions to licensed 
outlets, establishment of infection 
control programs in hospitals, and 
vigilance against counterfeit drugs 
by restricting marketing authoriza-
tion to those anti-infective drugs 
meeting international standards of 
quality, safety, and efficacy. Finally, 
the development of simple diag-
nostic tests and technologies that 
facilitate accurate diagnosis would 
permit more sparing use of anti-
infective drugs.
Farmers and policy-makers should 
be educated about the appropriate 
use of anti-infective drugs in animal 
husbandry, aquaculture, and farm-
ing. In particular, they should under-
stand the importance of anti-infec-
tive drugs in human health, the need 
to prevent infection by vaccinating 
animals when possible, and the need 
to stop using anti-infective drugs for 
promoting growth of livestock. It is 
often those working in human public 
health who are most able to convince 
those in the animal and agricultural 
industries about the importance of 
safe anti-infective drug use. In addi-
tion, safe levels of residues from anti-
infective drugs in animal and plant 
products for human consumption 
should be established, and regula-
tion of the bulk use of anti-infective 
drugs should be enforced through 
legislation at the national level.
The Future
Resistance to anti-infective drugs 
is an urgent public health problem 
threatening the treatment and control 
of infectious diseases ranging from  Elsevier Inc.those that have long been endemic 
in human populations—malaria, 
TB, and sexually transmitted infec-
tions—to those that have recently 
emerged and become endemic 
such as HIV. Drug resistance is also 
a threat to the control of seasonally 
occurring infections such as men-
ingitis and influenza, and to those 
that pose pandemic threats such as 
the H5N1 strain of avian influenza A. 
Drug-resistant pathogens—whether 
parasites, bacteria, or viruses—can 
no longer be effectively treated with 
common anti-infective drugs. The 
risk is great that because of drug 
resistance many more people will die 
from infectious diseases, and infec-
tions associated with major surgery 
and invasive hospital procedures will 
become more dangerous.
One of the major responses of 
medical workers to the problem of 
drug resistance has been to switch 
patients from older to newer drugs. 
Although effective initially, this strat-
egy has resulted in the emergence 
of resistance to the newer drugs. 
This, combined with a declining 
investment in research and develop-
ment of new classes of anti-infective 
drugs, has serious consequences 
for public health.
The ultimate solution to anti-infec-
tive drug resistance is prevention of 
infection through vaccination, and 
continued research and development 
of vaccines is an important part of any 
strategy to address drug resistance. 
Smallpox, which killed approximately 
3 million persons each year as recently 
as 1967, has been eradicated using an 
effective and widely available vaccine 
(Fenner et al., 1988), and poliomyeli-
tis also appears in line for eradication 
because of an effective vaccine (Hey-
mann and Aylward, 2004). Eradication 
of these viral diseases has pre-empted 
the need for antiviral drugs, and resist-
ance has therefore not been an issue. 
Effective use of vaccines has, in fact, 
shifted infectious disease morbidity 
and mortality away from those dis-
eases for which vaccines exist to those 
infectious diseases for which there are 
no preventive vaccines, and for which 
anti-infective drug resistance is now a 
major risk.
The urgent need to combat drug 
resistance demands three major 
responses: conservation of existing 
anti-infective drugs through prudent 
use and investment in research and 
development both for new anti-infec-
tive drugs and for vaccines, which 
are the ultimate solution to infection 
and drug resistance.
ReFeReNCes
Armstrong, G.L., Conn, L.A., and Pinner, R.W. 
(1999). JAMA 281, 61–66.
CDC. (2005). Centers for Disease Control and 
Prevention. High levels of adamantine resis-
tance among influenza A (H3N2) viruses and in-
terim guidelines for use of antivital agents, Unit-
ed States, 2005 -06 influenza season. MMWR 
at http://www.cdc.gov/flu/han011406.htm.
Cosgrove, S.E. (2006). Clin. Infect. Dis. 42 Sup-pl. 2, S82–S89.
Curtis, V., and Cairncross, S. (2003). Lancet In-
fect. Dis. 5, 275–281.
de Jong, M.D., Tran, T.T., Truong, H.K., Vo, M.H., 
Smith, G.J., Nguyen, V.C., Bach, V.C., Phan, 
T.Q., Do, Q.H., Guan, Y., et al. (2005). N. Engl. J. 
Med. 353, 2667–2672.
Dye, C., Espinal, M.A., Watt, C.J., Mbiaga, M., 
and Williams, B.G. (2002). J. Infect. Dis. 185, 
1197–1202.
Escoto-Delgadillo, M., Vazquez-Valls, E., 
Ramirez-Rodriguez, M., Corona-Nakamura, A., 
Amaya-Tapia, G., Quintero-Perez, N., Panduro-
Cerda, A., and Torres-Mendoza, B.M. (2005). 
HIV Med. 6, 403–409.
Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., 
and Ladnyi, I.D. (1988). Smallpox and Its Eradi-
cation. (Geneva: World Health Organization).
Heymann, D.L., and Aylward, R.B. (2004). N. 
Engl. J. Med. 351, 1275–1277.
Jung, M., Lee, K., Kim, H., and Park, M. (2004). Cell 124, FebCurr. Med. Chem. 11, 1265–1284.
Kondro, W. (1997). Lancet 349, 1156.
Levy, S.B. (1992). The Antibiotic Paradox: How 
Miracle Drugs Are Destroying the Miracle. (New 
York: Plenum Press).
NAS (1998). US Environmental Protection 
Agency in Antimicrobial Resistance. Issues and 
Options, Forum on Emerging Infections page 53 
(Washington, DC: National Academy Press).
Suttajit, S., Wagner, A.K., Tantipidoke, R., 
Ross-Degnan, D., and Sitthi-amorn, C. (2005). 
Southeast Asian J. Trop. Med. Public Health 36, 
489–497.
WHO. (1999). Removing Obstacles to Healthy 
Development. http://www.who.int/infectious-
disease-report/index-rpt99.html.
WHO. (2001). Global strategy for containment of 
antimicrobial resistance. Geneva, World Health 
Organization (WHO/CDS/CSR/DRS/2001.2). 
Further information available at http://www.
who.int/emc/amr.html.ruary 24, 2006 ©2006 Elsevier Inc. 675
